What is Jnana Therapeutics?
Jnana Therapeutics is at the forefront of drug discovery, utilizing its proprietary RAPID platform to systematically develop small molecule medicines with remarkable speed and efficiency. The company's focus spans critical therapeutic areas, including phenylketonuria (PKU) and various immune-mediated diseases. By targeting previously inaccessible high-value therapeutic targets, Jnana Therapeutics is poised to revolutionize the drug discovery process and enhance treatment paradigms for challenging conditions.
How much funding has Jnana Therapeutics raised?
Jnana Therapeutics has raised a total of $207M across 3 funding rounds:
Series A
$50M
Series B
$50M
Series C
$107M
Series A (2017): $50M, investors not publicly disclosed
Series B (2021): $50M led by Polaris Partners, AbbVie Ventures, Avalon Ventures, RA Capital Management, Versant Ventures, and Pfizer Ventures
Series C (2022): $107M supported by Pfizer Ventures, Polaris Partners, Versant Ventures, Avalon Ventures, and RA Capital Management
Key Investors in Jnana Therapeutics
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, known for partnering with entrepreneurs to foster growth and innovation.
Avalon Ventures
Avalon Ventures is a seasoned venture capital firm with a long-standing focus on seed and early-stage companies in life sciences and IT, driven by a team of experienced entrepreneurs.
Versant Ventures
Versant Ventures partners with entrepreneurs globally to build and fund innovative biotechnology companies, leveraging extensive experience and significant capital to drive scientific discoveries.
What's next for Jnana Therapeutics?
The recent major strategic investment positions Jnana Therapeutics for accelerated growth and expanded research and development initiatives. This Series C financing is expected to fuel the advancement of its pipeline, potentially leading to new therapeutic breakthroughs and strategic partnerships. The company's commitment to unlocking difficult-to-treat targets suggests a future focused on addressing unmet medical needs and solidifying its role as an innovator in the biopharmaceutical landscape.
See full Jnana Therapeutics company page
